Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is …
Biotechnology
CA, Burnaby [HQ]
XENE/Financial Reporting
Income Statements
13 Sheets · Starting from 2023In Million USD. Margins, Growth Rates In %
| Metric | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.00 | 14.00 | 27.00 | 28.00 | 15.00 | 1.00 | - - | - - | 6.00 | 32.00 | 18.00 | 9.00 | - - | |
|
EPS
|
-1.32 | -0.47 | 0.42 | 4.11 | -1.10 | -1.48 | -1.71 | -1.78 | -1.60 | -0.83 | -1.81 | -2.07 | -2.73 | |
| Diluted in mil. | -1.23 | -0.44 | 0.39 | 3.28 | -1.10 | -1.48 | -1.71 | -1.78 | -1.60 | -0.83 | -1.81 | -2.07 | -2.73 | |
|
Profit
|
6.00 | 6.00 | 21.00 | 22.00 | 12.00 | - - | -25.00 | -6.00 | -32.00 | -18.00 | -57.00 | -96.00 | -3.00 | |
| Gross Margin | 100.00 | 48.84 | 77.30 | 79.19 | 82.27 | 38.21 | -8,122.83 | - - | -468.82 | -57.07 | -309.30 | -1,021.13 | - - | |
| Pre Tax | -11.00 | -4.00 | 12.00 | 13.00 | -15.00 | -22.00 | -30.00 | -34.00 | -41.00 | -29.00 | -78.00 | -125.00 | -182.00 | |
| Profit Margin | -173.34 | -30.06 | 43.98 | 45.89 | -101.12 | -1,275.49 | -9,872.67 | - - | -609.43 | -90.45 | -427.88 | -1,327.70 | - - | |
| ETR | -0.76 | -2.16 | 0.53 | - - | 6.59 | 7.91 | 6.09 | -14.24 | 0.06 | 0.88 | 0.01 | -0.09 | 0.16 | |
| Net | -11.00 | -4.00 | 12.00 | 13.00 | -15.00 | -22.00 | -30.00 | -34.00 | -41.00 | -28.00 | -78.00 | -125.00 | -182.00 | |
| Profit Margin | -173.34 | -30.06 | 43.98 | 45.89 | -101.12 | -1,275.49 | -9,872.67 | - - | -609.09 | -89.65 | -427.85 | -1,328.95 | - - | |
| EBITDA | -10.00 | -2.00 | 10.00 | 12.00 | -9.00 | -25.00 | -33.00 | -36.00 | -40.00 | -31.00 | -78.00 | -129.00 | -210.00 | |
| EBITDA Margin | -156.53 | -15.54 | 39.31 | 43.75 | -60.10 | -1,401.50 | -10,713.83 | - - | -586.28 | -97.31 | -428.45 | -1,368.91 | - - | |
| Operating Income | -12.00 | -3.00 | 9.00 | 11.00 | -9.00 | -24.00 | -32.00 | -38.00 | -42.00 | -31.00 | -78.00 | -129.00 | -214.00 | |
| Operating Margin | -175.11 | -22.04 | 35.50 | 39.15 | -60.10 | -1,376.43 | -10,474.28 | - - | -627.02 | -97.31 | -428.45 | -1,368.91 | - - | |
| Interest Income | - - | - - | - - | - - | - - | - - | - - | 1.00 | 2.00 | 2.00 | - - | 8.00 | 27.00 | |
| Loss | -19.00 | -17.00 | -17.00 | -17.00 | -24.00 | -26.00 | -32.00 | -38.00 | -49.00 | -63.00 | -97.00 | -138.00 | -214.00 | |
| Cost of Revenue | - - | -7.00 | -6.00 | -5.00 | -2.00 | -1.00 | -25.00 | -6.00 | -38.00 | -50.00 | -75.00 | -105.00 | -3.00 | |
|
Operating Expenses
|
-19.00 | -17.00 | -17.00 | -17.00 | -24.00 | -26.00 | -32.00 | -32.00 | -49.00 | -63.00 | -97.00 | -138.00 | -210.00 | |
| R&D | -12.00 | -10.00 | -12.00 | -11.00 | -15.00 | -19.00 | -25.00 | -23.00 | -38.00 | -50.00 | -75.00 | -105.00 | -167.00 | |
| G&A | -6.00 | -7.00 | -5.00 | -5.00 | -9.00 | -6.00 | -7.00 | -8.00 | -10.00 | -12.00 | -21.00 | -32.00 | -46.00 | |
| SG&A | -6.00 | -7.00 | -5.00 | -5.00 | -9.00 | -6.00 | -7.00 | -8.00 | -10.00 | -12.00 | -21.00 | -32.00 | -43.00 | |
| S&M | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | -3.00 | |
| Depreciation and Amortization | -1.00 | - - | - - | - - | -1.00 | - - | - - | - - | - - | - - | - - | -1.00 | -3.00 | |
| Interest Expenses | - - | - - | - - | - - | - - | - - | - - | -1.00 | -1.00 | - - | - - | -5.00 | - - | |
| Other Expenses | - - | -1.00 | -2.00 | -1.00 | -6.00 | -1.00 | -1.00 | -3.00 | -1.00 | -2.00 | - - | -3.00 | -31.00 | |
|
WA Shares Outstanding
|
9.00 | 9.00 | 9.00 | 3.00 | 14.00 | 15.00 | 17.00 | 19.00 | 25.00 | 34.00 | 43.00 | 60.00 | 66.00 | |
| Diluted | 9.00 | 9.00 | 9.00 | 3.00 | 14.00 | 15.00 | 18.00 | 19.00 | 25.00 | 34.00 | 43.00 | 60.00 | 66.00 |